Almost 7 million prescriptions for antipsychotic drugs were issued outside hospital in England in 2008, an increase of 48% since 1998. Data from the USA also indicate dramatically increased rates of prescription of antipsychotics to young people over recent years. Ideas about the benefits of early drug treatment in psychosis, along with other factors such as the marketing of bipolar disorder, are likely to have contributed to the increasing prescription of these drugs.

The importance of starting drug treatment early, and of continuing treatment in people who would like to stop, is often justified by the prevalent belief that schizophrenia or psychosis involves a progressive loss of brain tissue that can be arrested or reduced by treatment with antipsychotic drugs. Accordingly, the drugs are sometimes referred to as having ‘neuroprotective’ properties. This belief is founded on a variety of evidence, all of which is debatable and open to other interpretations.

Almost 7 million prescriptions for antipsychotic drugs were issued outside hospital in England in 2008, an increase of 48% since 1998. Data from the USA also indicate dramatically increased rates of prescription of antipsychotics to young people over recent years. Ideas about the benefits of early drug treatment in psychosis, along with other factors such as the marketing of bipolar disorder, are likely to have contributed to the increasing prescription of these drugs.

The importance of starting drug treatment early, and of continuing treatment in people who would like to stop, is often justified by the prevalent belief that schizophrenia or psychosis involves a progressive loss of brain tissue that can be arrested or reduced by treatment with antipsychotic drugs. Accordingly, the drugs are sometimes referred to as having ‘neuroprotective’ properties. This belief is founded on a variety of evidence, all of which is debatable and open to other interpretations.

Summary
The idea that psychotic disorders are characterised by progressive neurodegeneration that can be reversed by drug treatment is used to justify early treatment of increasing numbers of mostly young people. I argue that there is little evidence to support the view that old- or new-generation antipsychotics are ‘neuroprotective’, and some evidence that the drugs themselves may be responsible for the decline in brain matter observed in some studies.

Declaration of interest
J.M. is the co-chair person of the Critical Psychiatry Network.

Editorial
Questioning the ‘neuroprotective’ hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia?
Joanna Moncrieff

Almost 7 million prescriptions for antipsychotic drugs were issued outside hospital in England in 2008, an increase of 48% since 1998. Data from the USA also indicate dramatically increased rates of prescription of antipsychotics to young people over recent years. Ideas about the benefits of early drug treatment in psychosis, along with other factors such as the marketing of bipolar disorder, are likely to have contributed to the increasing prescription of these drugs.

The importance of starting drug treatment early, and of continuing treatment in people who would like to stop, is often justified by the prevalent belief that schizophrenia or psychosis involves a progressive loss of brain tissue that can be arrested or reduced by treatment with antipsychotic drugs. Accordingly, the drugs are sometimes referred to as having ‘neuroprotective’ properties. This belief is founded on a variety of evidence, all of which is debatable and open to other interpretations.

Brain imaging research
The main area believed to support the ‘neuroprotection’ hypothesis is brain imaging research illustrating that people with schizophrenia or psychosis show a progressive reduction in brain volume and an enlargement of ventricles and cerebral spinal fluid. All such studies, however, involve people who have taken long-term antipsychotic medication. A large study showing greater decline in brain volume in patients with first-episode psychosis taking haloperidol compared with olanzapine has been interpreted as indicating the neuroprotective effects of olanzapine. The authors acknowledged, however, that the study might also be interpreted as demonstrating differential drug-induced changes. Supporting the latter interpretation, a study of macaque monkeys treated with therapeutic doses of olanzapine and haloperidol for 18 months found an 8% reduction in mean fresh brain weight in monkeys treated with haloperidol and 11% in those on olanzapine compared with non-drug-treated controls.

The great majority of studies of individuals who are drug-naive or have received only minimal treatment, do not show the global deficit in brain volume commonly associated with patients who have received drug treatment, including, most importantly, the only three studies involving people with long-term conditions who had not been exposed to drug treatment. Results from two studies of people considered to be at high risk of psychosis are also believed to demonstrate progressive brain tissue loss prior to and in the early stages of psychotic illness. Many of the Australian cohort, however, were taking antipsychotic medication during some of the follow-up period. In the Edinburgh study, high-risk individuals who progressed to psychosis showed greater temporal lobe reduction than those who did not progress, but did not differ from controls. Overall, therefore, imaging studies provide little evidence of progressive brain tissue loss in non-drug-treated patients with schizophrenia. Moreover, the effects of drug treatment have not been excluded as a cause of the tissue loss seen in some studies of drug-treated patients.

Neuropathological findings
Post-mortem studies have generally not found the large-scale neuronal loss and gliosis characteristic of neurodegenerative disorders in the brains of people with schizophrenia, although there is some evidence of local reduction of neuronal sub-populations and local loss of dendritic spines and length. Again, however, all studies have involved people on long-term medication. Some studies with drug-naive patients have found reduced serum levels of brain derived neurotrophic factor (BDNF), but this finding is not specific to schizophrenia, and BDNF has also been found to be involved in mood disorders and the stress response. Although schizophrenia has been suggested to involve increased or abnormal apoptosis, several studies confirm that markers of apoptosis in neurodegenerative disorders such as Alzheimer’s disease are not raised in post-mortem tissue from patients with chronic schizophrenia, and the role of apoptosis earlier on in the condition remains speculative.

Duration of untreated psychosis
Another frequently cited, indirect strand of evidence for the hypothesis that schizophrenia arises from progressive brain pathology that can be arrested by drug treatment is the association...
found in some studies (although not all) between the duration of untreated psychosis and outcome. However, it has long been recognised that conditions with a long and insidious early course are frequently more severe than those with a sudden onset. Duration of untreated psychosis is strongly related to mode of onset and other potential confounding factors.

Trials of early intervention have shown some positive results, but have not analysed the role of medication over and above other aspects of the intervention, and long-term results are disappointing (reviewed in Bosanac et al.). Two trials of drug treatment for young people at high risk of psychosis suggested that the rate of conversion to psychosis was reduced, although not by a statistically significant degree in the larger of the two trials. A larger naturalistic study has so far found that drug treatment has not reduced the onset of psychosis.

References

There used to be surgeons too . . .

Shabbir Amanullah

The days of the conventional physician seem numbered and one can almost see the day when surgical operations will be performed by robots possibly monitored by a surgeon initially. Surgical emergencies will be dealt with by mobile surgical units that are self-contained and whiz around town performing operations quietly and efficiently. After all, most of the time diagnoses are based on symptom clusters and a well-programmed robot can do the same, with no room for errors due to anxiety, substance misuse, anger, exhaustion, etc., effectively using advanced imaging techniques. Of course, reporting will be outsourced!

Imagine an accident and emergency department with no emotional tension. No anger at the return of a difficult patient. Just a series of television screens and plug-in memory cards in the mobile units. Whole body scans for those with flu-like symptoms and no fears of cross-infections or iatrogenic infections. No more MRSA or VRA (unless we insist that they wear ties!).

It seems increasingly likely that with rapid progress in science we as physicians may be a dying breed. All except, possibly, psychiatry. Grief will be a major issue and so too robot phobias. Those of our medical colleagues looking for work may come for reminiscence therapy – ‘Remember the good old days, when we used to . . .’ There will of course be those who grieve the loss of the human physician. My message to medical students: join psychiatry and remain employed!

The British Journal of Psychiatry (2011) 198, 87. doi: 10.1192/bjp.198.2.87
Questioning the 'neuroprotective' hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia?

Joanna Moncrieff

Access the most recent version at DOI: 10.1192/bjp.bp.110.085795

References
This article cites 22 articles, 3 of which you can access for free at:
http://bjp.rcpsych.org/content/198/2/85#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at /letters/submit/bjprcpsych;198/2/85

Downloaded from http://bjp.rcpsych.org/ on September 23, 2016
Published by The Royal College of Psychiatrists